GlassScriptPhysician profile
Kevin S Jo
NPI 1003823683
$5,051.48
in general payments reported to CMS, 2019-2025
36 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $417 · 2021: $125 · 2022: $241 · 2023: $540 · 2024: $911 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $974.81 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $891.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $848.69 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $445.09 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $308.21 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $143.66 | 2019-2024 | Rebyota |
| Ardelyx, INC. | $124.89 | 2023-2025 | Ibsrela |
| Pfizer INC. | $117.97 | 2019-2025 | |
| Madrigal Pharmaceuticals | $112.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $99.56 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $95.91 | 2024-2025 | Omvoh, Zepbound |
| Allergan, INC. | $87.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $79.61 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $73.43 | 2023-2025 | Sucraid |
| Genzyme Corporation | $65.43 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $53.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $51.24 | 2022-2025 | Dupixent |
| Amgen INC. | $45.93 | 2020-2025 | Uplizna |
| Alfasigma USA, INC. | $44.98 | 2020 | |
| Ucb, INC. | $43.46 | 2019 | |
| Nestle Healthcare Nutrition INC. | $38.13 | 2022-2023 | |
| Redhill Biopharma INC. | $37.37 | 2020-2021 | |
| Shionogi INC | $33.23 | 2019 | |
| Merck Sharp & Dohme LLC | $30.71 | 2019-2020 | |
| Exact Sciences Corporation | $25.35 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $24.98 | 2019 | |
| Daiichi Sankyo INC. | $21.10 | 2021 | |
| Intercept Pharmaceuticals, INC. | $20.99 | 2019 | |
| Celltrion USA INC. | $20.55 | 2025 | Vegzelma |
| Conmed Corporation | $19.13 | 2019 | |
| Ethicon US, LLC | $15.35 | 2022 | |
| Alcresta Therapeutics, INC. | $15.00 | 2019 | |
| Braintree Laboratories, INC. | $13.83 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.